Umeclidinium bromide

Last updated
Umeclidinium bromide
Umeclidinium bromide.svg
Umeclidinium bromide 3D.png
Clinical data
Trade names Incruse Ellipta
Other namesGSK573719A
License data
Routes of
administration 		Inhalation (DPI)
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding ~89% [3]
Metabolism Liver (CYP2D6)
Elimination half-life 11 hours
Excretion Feces (58%) and urine (22%)
Identifiers
  • Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard 100.166.375 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C29H34BrNO2
Molar mass 508.500 g·mol−1
3D model (JSmol)
  • OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2.[Br-]
  • InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1
  • Key:PEJHHXHHNGORMP-UHFFFAOYSA-M

Umeclidinium bromide, sold under the brand name Incruse Ellipta among others, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol), [5] [6] [7] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol. [8]

It is on the World Health Organization's List of Essential Medicines. [9] In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [10] [11]

References

  1. ↑ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  2. ↑ "Product monograph brand safety updates". Health Canada . 7 July 2016. Retrieved 3 April 2024.
  3. 1 2 3 "Incruse Ellipta- umeclidinium aerosol, powder". DailyMed. 13 December 2023. Retrieved 28 March 2025.
  4. ↑ "Rolufta Ellipta (previously Rolufta)". European Medicines Agency (EMA). 20 March 2017. Retrieved 28 March 2025.
  5. ↑ "Anoro Ellipta- umeclidinium bromide and vilanterol trifenatate powder". DailyMed. 2 June 2023. Retrieved 28 March 2025.
  6. ↑ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID   24004659. S2CID   5744282.
  7. ↑ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
  8. ↑ "Trelegy Ellipta- fluticasone furoate, umeclidinium bromide and vilanterol trifenatate powder". DailyMed. 2 June 2023. Retrieved 28 March 2025.
  9. ↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl: 10665/345533 . WHO/MHP/HPS/EML/2021.02.
  10. ↑ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  11. ↑ "Umeclidinium - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.